1. Medline closed its IPO, raising $29 per share for 248 million shares. 2. Proceeds will be used to reduce debt from secured loans. 3. Company aims to strengthen capital structure and fund general purposes. 4. Goldman Sachs and others led the offering underwriters. 5. Medline remains the largest medical-surgical product provider.
FAQ
Why Bullish?
The significant capital raised will strengthen Medline's financial position, similar to past IPOs boosting company valuations.
How important is it?
The IPO's success and debt repayment plans directly enhance Medline's market position and financial outlook.
Why Short Term?
Immediate financial stability from debt reduction can positively influence MDLN's stock in the near term.
Medline Inc. Completes Upsized Initial Public Offering
NORTHFIELD, Ill., Dec. 18, 2025 — Medline Inc. (Nasdaq: MDLN) has announced the successful closure of its upsized initial public offering (IPO), comprising 248,439,654 shares of Class A common stock at a price of $29.00 per share. This offering includes the full exercise of the underwriters' option to purchase an additional 32,405,172 shares of the company's stock.
Use of Proceeds from the IPO
Medline plans to utilize the net proceeds from the sale of 179,000,000 shares primarily to repay debt under its senior secured term loan facilities. The remaining funds will be allocated to general corporate purposes and to cover the offering's expenses. Additionally, proceeds from the issuance of 37,034,482 shares, alongside the shares resulting from the exercised option, will be directed toward purchasing or redeeming outstanding equity interests from specific pre-IPO stakeholders.
Management and Underwriting Team
The IPO was coordinated by several prominent financial institutions, including Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan, who served as the lead bookrunning managers. A range of other banks acted as bookrunning managers in this offering, demonstrating the strong support from the investment community.
- Goldman Sachs & Co. LLC
- Morgan Stanley
- BofA Securities
- J.P. Morgan
- Barclays
- Citigroup
- Deutsche Bank Securities
- UBS Investment Bank
- Jefferies
- Evercore ISI
Registration and Legal Information
A registration statement related to this offering was filed with the Securities and Exchange Commission and was declared effective on December 16, 2025. The IPO was conducted exclusively via a prospectus, available through the underwriting team. Interested parties may obtain copies from the respective prospectus departments of the managing banks.
About Medline Inc.
Medline, recognized as the largest supplier of medical-surgical products, operates globally, providing supply chain solutions across both acute and non-acute healthcare settings. Headquartered in Northfield, Illinois, the company boasts a workforce of over 43,000 and extends its reach to more than 100 countries worldwide.
Forward-Looking Statements
This announcement may contain forward-looking statements reflecting expectations about the company's future financial performance and operational strategy. Such statements involve risks and uncertainties, leading actual results to vary significantly from projections.
Contact Information
For further information, contact:
- Karen King, Global Head Investor Relations, +1.847.247.7222, Karen.King@medline.com
- Ben Fox, Vice President, Corporate Communications, +1.224.327.9999, BeFox@medline.com